Evidence of Mapping Malpractice? A Review of Mapping Algorithm Usage in NICE Health Technology Appraisals

Author(s)

George Bungey, MSc1, Claire Spencer, MSc1, Solène De Boisvilliers, MSc2, Margherita D'Errico, MSc3, Eszter Nagy, MPhil4, Gábor Szabó, MSc5, Kerry Winter, BSc, MSc1, Pedro Saramago, MSc, PhD1.
1PPD™ Evidera™ Health Economics & Market Access, Thermo Fisher Scientific, London, United Kingdom, 2PPD™ Evidera™ Health Economics & Market Access, Thermo Fisher Scientific, Paris, France, 3PPD™ Evidera™ Health Economics & Market Access, Thermo Fisher Scientific, Milan, Italy, 4PPD™ Evidera™ Health Economics & Market Access, Thermo Fisher Scientific, Liverpool, United Kingdom, 5PPD™ Evidera™ Health Economics & Market Access, Thermo Fisher Scientific, Budapest, Hungary.
OBJECTIVES: National Institute of Health and Care Excellence (NICE) methods guidance indicates EQ-5D-3L as the preferred health-related quality of life measure. As EQ-5D-3L data may not always be available, mapping can be applied to other non-preference or preference-based measures to generate EQ-5D-3L utilities, with prior literature identifying mapping in TAs usage in a quarter of NICE submissions. Our review sought to evaluate the frequency of usage, as well as key characteristics, of mapping algorithm usage in NICE appraisals over a 5-year period.
METHODS: NICE appraisals were screened for relevance between 1st March 2020 to February 28th 2025. Terminated or superseded appraisals, along with appraisals without cost-utility analyses, were excluded in first pass review. In second pass, appraisals without mapping conducted were excluded, with remaining appraisals reviewed to assess the characteristics and justifications for mapping algorithms applied.
RESULTS: Of 626 appraisals screened, 442 (70.6%) were excluded for not including descriptions of mapping algorithm usage (261 and 181 in first and second pass, respectively). Of 184 appraisals included, 126 (68.5%) used cross-walking from EQ-5D-5L to EQ-5D-3L, with 75/126 (60%) using the van Hout 2012 crosswalk algorithm. 64/184 (35%) used other types of utility mapping, most commonly (37.5%; 24/64) from EORTC-QLQ-C30 to EQ-5D-3L. Among these, mapping algorithms were most commonly identified from prior NICE appraisals, literature review or the HERC database. More than half either did not report selection criteria or relied on precedence from prior appraisals. While some critique identification and selection criteria was provided, EAG feedback appeared highly specific rather than based on comprehensive review methods.
CONCLUSIONS: Our review found that mapping still plays an important role in NICE appraisals, although non-cross-walk related mapping usage appears relatively infrequent (~10% of appraisals screened). Mapping algorithm identification methods were somewhat inconsistent across appraisals with generally limited reporting of selection criteria, indicating an unmet need for clearer guidelines.

Conference/Value in Health Info

2025-11, ISPOR Europe 2025, Glasgow, Scotland

Value in Health, Volume 28, Issue S2

Code

HTA137

Topic

Economic Evaluation, Health Technology Assessment, Patient-Centered Research

Topic Subcategory

Decision & Deliberative Processes

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×